Union Health Ministry Proposes Amendment to New Drugs and Clinical Trials Rules, 2019 to Bring Antimicrobials under Central Regulatory Oversight
Published: · Updated:
Source: PIB (Press Information Bureau) · Read the original ↗
Summary
- The Health Ministry proposed, through draft Gazette Notification G.S.R. 983(E) dated 6 November, to add "antimicrobials" to the definition of 'New Drug' under Rule 2(1)(w)(v) of the New Drugs and Clinical Trials Rules, 2019.
- Manufacturers would first need permission from the Central Licensing Authority (CLA) before applying to the State Licensing Authority (SLA) for a manufacturing licence.
- The aim is to check quality, safety and efficacy, and to curb antimicrobial resistance (AMR).
- Objections and suggestions are invited within 30 days.
Key facts for Prelims
- NDCT Rules, 2019 are made under the Drugs and Cosmetics Act, 1940 (Section 33), after consulting the Drugs Technical Advisory Board.
- Central Licensing Authority = Drugs Controller (General) of India (DCGI/CDSCO, Health Ministry). State Licensing Authority issues manufacturing licences.
- The draft amends Rule 2(1)(w)(v), the "New Drug" definition, via G.S.R. 983(E).
- Antimicrobial resistance: the G20 New Delhi Leaders' Declaration (India's G20 presidency) backed a One Health approach to AMR.
- One Health = integrated approach to human, animal and environmental health.
- BA/BE = bioavailability/bioequivalence; stability studies test shelf-life and quality over time.
- NAP-AMR 2.0 covers 2025–29 and succeeds the 2017–21 plan.
- Entry 19, Concurrent List: Drugs and poisons.
Data and details
- Draft notification: G.S.R. 983(E), 6 November.
- Public comment window: 30 days from the date copies of the Gazette are made available to the public.
- Comments go to the Under Secretary (Drugs), MoHFW, Kartavya Bhawan-1, New Delhi–110001, or by email to the drugs division.
- Draft text is on the e-Gazette (2026, file 278020).
- Stated reasons:
- Manufacturing licences for antimicrobials have been granted without adequate scrutiny, including studies such as BA/BE and stability.
- Absence of these assessments may compromise quality, safety and efficacy.
- Substandard or ineffective antimicrobials can contribute to the development and spread of AMR.
- Process change: manufacturers must get CLA permission before applying to the SLA for a manufacturing licence.
- Not in the release: which antimicrobial classes are covered, whether already-licensed products are grandfathered, timelines for CLA decisions, and any data on AMR burden.
Static–dynamic linkage
- Drug regulation in India is split between the Centre and States. Under the Drugs and Cosmetics Act, 1940, the Centre approves new drugs and clinical trials, while State licensing authorities issue manufacturing licences. Entry 19 of the Concurrent List covers drugs and poisons.
- A "New Drug" label triggers central scrutiny, with data requirements such as bioavailability/bioequivalence (BA/BE) and stability studies, before State licensing.
- AMR is a "silent pandemic" driven by overuse and misuse of antibiotics, and also by poor-quality antimicrobials that give sub-therapeutic exposure. Tightening pre-licensing scrutiny is a supply-side measure, complementing stewardship and prescription controls.
Syllabus mapping: GS2 – Health: regulation of drugs, Centre-State roles | GS3 – S&T: biotechnology and pharma regulation | GS3 – Environment/GS2 – Health: AMR and One Health
Background primer
New Drugs and Clinical Trials Rules, 2019 (NDCT Rules)
- What it is:
- Rules made under Section 33 of the Drugs and Cosmetics Act, 1940, after consulting the Drugs Technical Advisory Board.
Central Drugs Standard Control Organization (CDSCO) role
Additional context
- National Action Plan on AMR 2.0:
- The Union Health Minister launched it on 18 November 2025, covering 2025–2029.
- It builds on the gaps in the first plan (2017–2021) and aligns with the WHO Global Action Plan.
- It includes action plans for each key stakeholder ministry with timelines and budgets.
- For the first time it mandates systematic surveillance of antibiotic residues and resistant pathogens in the environment.
- It also promotes prescription auditing and antibiotic stewardship.
- The launch was timed with the WHO's World AMR Awareness Week (18–24 November). The present draft release (19 Nov 2026) also falls within that week.
- A critique of the plan: Major AMR determinants fall under State jurisdiction, and the plan lacks a mechanism to ensure States develop and implement AMR action plans. This is relevant because the present draft touches the Centre–State licensing split.
- NAP-AMR 2.0 also covers monitoring of pharmaceutical waste and regulation of antimicrobial and pesticide use in crops.
Mains dimensions
- Regulatory gap. The ministry's own premise is that licences were being granted without BA/BE or stability data. The reform moves a decision upstream to the CLA. This is a centralisation of oversight in an area where States historically license.
- Link to AMR. Substandard antimicrobials can drive resistance, and the G20 reference positions this as a global One Health issue. Supply-side quality control complements demand-side stewardship (prescription auditing, antibiotic stewardship) in NAP-AMR 2.0.
- Federal dimension. The model is dual control: CLA first, SLA next. This could improve uniformity, but there is a risk of delay and duplication. The draft sets no timelines in the release. NDCT elsewhere has 90-working-day deemed approvals for trial permissions, but whether anything similar applies here is not stated.
- Industry and access trade-offs. More data requirements raise compliance costs, especially for smaller manufacturers, and may delay generics. The aim is to avoid substandard drugs without causing shortages of essential antibiotics (analytical point).
- Environment angle. NAP-AMR 2.0 provides for environmental residue surveillance and monitoring of pharmaceutical waste, so drug quality, effluents and resistance are linked.
- Process legitimacy. The pre-legislative consultation (draft rules with a 30-day window) reflects the standard rule-making process.
- Way forward. Phased applicability, clear timelines, harmonised data requirements, strong State enforcement capacity, post-market surveillance, and continued emphasis on stewardship and prescription control.
Possible Mains question
**GS2/GS3, 10 marks:** "India proposes to bring antimicrobials under the 'new drug' regulatory framework with prior Central approval. Discuss the rationale and challenges of this measure in the fight against antimicrobial resistance."
Related topics
- Drugs and Cosmetics Act, 1940; CDSCO; Drugs Technical Advisory Board; Jan Vishwas (decriminalisation) debates
- AMR: One Health, NAP-AMR 2.0, World AMR Awareness Week, WHO Global Action Plan
- Substandard and spurious drugs; Schedule M (good manufacturing practices) reforms
- Centre-State division of health powers; Concurrent List
- Pharma waste/effluents and environmental regulation
Topics: GS2
All current affairs of 19 November 2026 → · UPSC Current Affairs